JPRN-UMIN000005386已完成2 期
Phase II trial of bendamustine plus rituximab treatment for relapsed or refractory low grade B-cell non Hodgkin lymphoma - Phase II trial of BR treatment for relapsed or refractory low grade B-NH
Kanagawa Clinical Oncology study Group0 个研究点目标入组 44 人开始时间: 2011年4月7日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1: pregnancy or breast feeding 2: any other malignancy 3: mental illness 4: positive test for HBV surface antigen 5: positive test for HCV anti body 6: positive test for HIV anti body 7: lymphoma cell count > 25 x 10*9/L in peripheral blood 8: post allogenic stem cell transplantation 9: interstitial pneumonia or pulmonary fibrosis 10: central nervous system involvement with lymphoma 11: history of bendamustine treatment 12: inappropriate for rituximab treatment 13: severe hypersensitivity for any drugs 14: inappropriate for entry by physician's decision
研究者
相似试验
已完成
2 期
Phase II study of Bendamustine-Rituximab therapy for CD20-positive untreated and advanced follicular lymphoma with poor response to R-CHOP therapyuntreated and advanced follicular lymphomaJPRN-UMIN000013795Department of Hematology and Rheumatology,Kinki University Faculty of Medicine60
已完成
2 期
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaDiffuse Large B-Cell LymphomaNCT00831597Pharmatech61
已完成
2 期
Phase II study of bendamustine, rituximab and cytarabine for patients with relapsed or refractory follicular lymphoma or mantle cell lymphomarelapsed or refractory follicular lymphoma or mantle cell lymphomaJPRN-UMIN000009797Gifu University Hospital13
已完成
2 期
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT03609593Nicole Lamanna42
进行中（未招募）
1 期
A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30+ peripheral T-cell lymphoma in first salvage setting: the BBV regimen.Hodgkin’s lymphoma and CD30+ peripheral T-cell lymphomaMedDRA version: 22.0Level: LLTClassification code 10012877Term: Diffuse large cell lymphoma (Peripheral T-cell lymphoma unspecified) (Working Formulation) recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2014-005382-79-ITFONDAZIONE ITALIANA LINFOMI ONLUS65